针对非小细胞肺癌中KRAS突变的临床进展和挑战
Simone E Dekker1,2, Lei Deng1,2
1Division of Hematology and Oncology, Department of Medicine, School of Medicine, University of Washington, Seattle, WA 98195, USA.
Cancers
|November 27, 2024
概括
现在,KRAS G12C突变可以在非小细胞肺癌中作为点. 新的KRAS抑制剂显示出希望,为改善治疗提供了希望,超出目前的适度疗效.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- KRAS突变是非小细胞肺癌 (NSCLC) 的关键驱动因素.
- 从历史上看,准KRAS一直是具有挑战性的,有很多药物开发失败的标志.
- 克拉斯G12C代表了第一个成功向的克拉斯突变.
研究的目的:
- 审查治疗KRAS突变NSCLC的临床进展.
- 讨论KRAS向疗法的挑战和进展.
- 专注于KRAS突变NSCLC的小分子抑制剂.
主要方法:
- 对KRAS抑制剂的临床试验数据的审查.
- 关于KRAS突变和向治疗的科学文献分析.
- 专注于小分子抑制剂的开发和有效性.
主要成果:
- 第一代KRAS G12C抑制剂显示出适度的疗效.
- 下一代具有更高强度的KRAS G12C抑制剂正在开发中.
- 针对其他KRAS亚变体的新兴疗法显示有希望的早期临床数据.
结论:
- 准KRAS G12C是NSCLC治疗的一个重大突破.
- 目前正在进行的研究正在扩大对KRAS突变NSCLC的治疗选择.
- 小分子抑制剂是推动KRAS向肺癌治疗的核心.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.8K
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K